In addition to being the main cause of glomerulonephritis in children, poststreptococcal glomerulonephritis (PSGN) has recently been shown in older patients, especially those with malignancy or diabetes mellitus. The pathogenesis of PSGN has been ascribed to activation of complement 3 (C3) of the alternative complement cascade which, along with immunoglobulin (Ig) G and IgM deposits, is observed in renal tissue. Our aim here is to discuss the probable causes of PSGN developing with isolated IgM deposition in a 52-year-old patient with essential thrombocytosis followed-up over the previous 3.5 years. These characteristics make our case the first to be reported in the literature. (J Nippon Med Sch 2015; 82: 59 63) 
Introduction
Poststreptococcal glomerulonephritis (PSGN) is a type of glomerulonephritis that develops following streptococcus-related throat and skin infections 1 . It affects children in countries with low levels of socioeconomic development 2 . In Europe and North America PSGN has begun being seen frequently in persons older than 60 years with diabetes mellitus and malignancies, users of intravenous drugs, and alcoholics 3 .
Myeloproliferative neoplasm (MPN) is a hematological disease characterized by clonal proliferation of granulocytic, megakaryocytic, or erythroid series progenitor cells.
Essential thrombocytosis (ET) is a type of MPN 4 . Various renal diseases have been reported in patients with ET
and include obstruction of the urinary tract by blood clots, bilateral acute kidney failure related to renal artery thrombosis, and various glomerular diseases 5 7 . However, the pathogenesis of renal diseases in both ET and other
MPNs is still unclear.
Our aim in this case report was to report, for the first time in the literature, PSGN in a patient with ET, which is known to accompany various renal diseases.
Case History
At a hospital where he had presented with hemoptysis 3.5 years previously while under observation for hypertension for 8 years and coronary artery disease for 4 years, a 52-year-old man was found to have a platelet count of 1,600×10 3 ! (×10 3 ! μL). Tests for JAK2 and bcr-abl in both specimens of peripheral blood and bone marrow aspirate were negative. Examination of the bone marrow showed increased cellularity, an increase in the number of megakaryocytes, clustering, abnormal localization, and dysplastic changes. The morphologies of both granulocytic and erythrocytic series were normal. On the basis of these findings ET was diagnosed, and treatment was started with hydroxyurea, 1 g in the morning and 500 mg in the evening. After a follow-up examination, treatment was started with allopurinol, 300 mg! day. Hematological
and biochemical values at follow-up are shown in Table   1 .
At the hospital where he had presented 3 weeks earlier with a fever of 38.5 , sore throat, and nausea, the patient was given an antipyretic and an antibiotic drug whose name he did not know and was then sent home.
Laboratory values at that time and at the hospital where he presented several times subsequently are shown in Ta infiltration, and capillary lumen occlusion ( Fig. 1, 2) . Immunofluorescence studies revealed granular capillary walls and mesangial deposits of immunoglobulin (Ig) M (Fig. 3) . Electron microscopic examination revealed electron-dense deposits in the subepithelial region within the basal membrane (Fig. 4) . On the basis of these findings, PSGN was suspected.
Treatment with methylprednisolone was started at a dosage of 1 mg! kg per day. We planned to continue treatment at this dosage for 1 month, to reduce the dosage, and then to stop treatment after 6 months. After 1 month of treatment, creatinine levels were close to normal. At follow-up after 6 months of treatment, renal function had returned to normal, and the microscopic hematuria and proteinuria had resolved.
Discussion
Edema developing in association with gross hematuria darkening from red to brown and a decrease in volume is one of the oldest clinical observations in nephrology 8 . Hydroxyurea is a widely used antimetabolite anticancer drug. It reduces the synthesis of deoxyribonucleotides through the inhibition of ribonuclease reductase 15 . Hydroxyurea can be used safely to treat patients with ET.
The most frequently seen side effects are pneumonitis and skin ulcers, while leukopenia is also observed, as with several other anticancer drugs 16 . Hydroxyurea has rarely been reported to impair renal function; this effect may be associated with tumor lysis syndrome and can lead to thrombotic microangiopathy 17, 18 . In the present case, the absence of such laboratory findings as hyperuricemia, hyperkalemia, and hyperphosphatemia ruled out tumor lysis syndrome-related kidney injury. Furthermore, histopathological examination ruled out thrombotic microangiopathy-related kidney injury. In light of our patient's history of throat infection, elevated levels of ASO, and histopathological findings supporting PSGN, we suspect the kidney injury in our patient was due to PSGN facilitated by leukopenia developing as the result of hydroxyurea use.
Another possible cause of impaired renal function in our patient is allopurinol. Allopurinol is an analog of hypoxanthine and is used to treat hyperuricemia. The most important side effect limiting its use is drug rash with eosinophilia and systemic symptoms syndrome, which affects the skin, kidneys, and liver 19 . However, because our patient did not have eosinophilia, systemic symptoms, or interstitial nephritis, we did not suspect renal involvement associated with allopurinol use.
In conclusion, the present case is, to our knowledge, the first to be reported of ET accompanied by PSGN and isolated IgM deposition. Several risk factors for the development of PSGN may be present, we recommend early antibiotic therapy and the monitoring of renal function. Also, we believe that monitoring leukocyte numbers is important in patients with ET treated with hydroxyurea and that greater care must be taken when infectious findings are present.
